<SEC-DOCUMENT>0001104659-20-140370.txt : 20201230
<SEC-HEADER>0001104659-20-140370.hdr.sgml : 20201230
<ACCEPTANCE-DATETIME>20201230080023
ACCESSION NUMBER:		0001104659-20-140370
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20201230
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201230
DATE AS OF CHANGE:		20201230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lipocine Inc.
		CENTRAL INDEX KEY:			0001535955
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990370688
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36357
		FILM NUMBER:		201424076

	BUSINESS ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108
		BUSINESS PHONE:		801 994 7383

	MAIL ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARATHON BAR CORP
		DATE OF NAME CHANGE:	20111130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2039447d3_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event Reported):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December 30, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="tm2039447d3_8kimg001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIPOCINE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File No. 001-36357</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99-0370688</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction <BR>
of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<BR>
 Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>675 Arapeen Drive, Suite 202</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Salt Lake City, Utah 84108</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(801) 994-7383</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Former name or former address, if changed
since last report: <B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933&nbsp;(17 CFR &sect; 230.405) or&nbsp;Rule 12b-2 of the Securities
Exchange Act of 1934&nbsp;(17 CFR &sect; 240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company </FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to&nbsp;Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to&nbsp;<U>Section 12(b)</U>&nbsp;of the Act</FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: rgb(204,204,204) 1pt solid; border-right: rgb(204,204,204) 1pt solid; border-bottom: Black 1pt solid; border-left: #CCCCCC 1pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="border-top: rgb(204,204,204) 1pt solid; border-right: rgb(204,204,204) 1pt solid; border-bottom: Black 1pt solid; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="border-top: rgb(204,204,204) 1pt solid; border-right: rgb(204,204,204) 1pt solid; border-bottom: Black 1pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which<BR>
 registered</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: #CCCCCC 1pt solid; border-left: #CCCCCC 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, par value $0.0001 per share</FONT></TD>
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: #CCCCCC 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LPCN</FONT></TD>
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: #CCCCCC 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NASDAQ Stock Market LLC</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;8.01</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other Events</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On December 30, 2020, the Company issued
a press release announcing an open label extension to the ongoing LPCN 1144 <I>LiFT</I> study. The press release is filed as Exhibit
99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed with this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 19%; padding-bottom: 12pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Exhibit No.</U></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 81%; padding-bottom: 12pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tm2039447d3_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1 </A></TD>
    <TD><A HREF="tm2039447d3_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release announcing Open Label Extension to Ongoing LPCN 1144 <I>LiFT
</I>Study </A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 85.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 85.5pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 85.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIPOCINE INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 30, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2039447d3_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"><IMG SRC="tm2039447d3_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Lipocine Announces Open Label Extension
to Ongoing LPCN 1144 <I>LiFT</I> Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SALT
LAKE CITY, December 30, 2020</B></FONT> -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage <FONT STYLE="background-color: white">biopharmaceutical
company focused on metabolic and endocrine disorders, today announced that it is enrolling patients into an open label extension
to the ongoing LPCN 1144 Phase 2 <I>LiFT</I> study based on investigator and patient interest in continuing treatment. The <I>LiFT</I></FONT>
(&quot;<B><I><U>Li</U></I></B>ver <B><I><U>F</U></I></B>at intervention with oral <B><I><U>T</U></I></B>estosterone&quot;) <FONT STYLE="background-color: white">clinical
study is a paired-biopsy study investigating LPCN 1144 in confirmed non-cirrhotic non-alcoholic steatohepatitis (&quot;NASH&quot;)
subjects.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">In the initial, double-blind
part of the <I>LiFT</I> study, patients were randomized to receive one of two treatments of LPCN 1144 or placebo over 36 weeks.
Patients who complete this portion will now have the option to enter the 36-week open label extension study, which is designed
to evaluate the long-term safety and tolerability of LPCN 1144 treatment. There is no placebo arm in the open label extension study,
and all patients will be treated with LPCN 1144. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">&ldquo;This extension
to our ongoing <I>LiFT</I> clinical study will allow us to collect additional data on LPCN 1144 for up to a total of 72 weeks of
therapy,&rdquo; said Dr. Mahesh Patel, Chairman, President and Chief Executive Officer of Lipocine. &ldquo;Patients who may have
received placebo during the initial, randomized part of the trial now have the opportunity to receive active drug.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">For more information on
<I>LiFT</I>, refer to NCT04134091.For more information on this open label extension study, refer to NCT04685993.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #444444">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>About
Lipocine</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Lipocine Inc. is a
clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery
technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107.
TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the
FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult
males.&nbsp;LPCN 1144, an oral product of bioidentical testosterone, recently completed a proof-of-concept clinical study
demonstrating the potential utility in the treatment of non-cirrhotic NASH.&nbsp;LPCN 1144 is currently being studied in a
Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a
next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when
administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral
prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral
hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted
orphan drug designation by the FDA. For more information. For more information, please visit<FONT STYLE="color: #444444">&nbsp;</FONT><U>www.lipocine.com</U><FONT STYLE="color: #444444">. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #444444">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #444444"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #444444">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B></B></FONT><FONT STYLE="background-color: white">This release contains &quot;forward-looking statements&quot; that are
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that
are not historical facts regarding Lipocine&rsquo;s product candidates and related clinical trials, the timing of completion of
clinical trials, including the&nbsp;LIFT&nbsp;clinical study, the potential uses and benefits of our product candidates, and our
product development efforts. Investors are cautioned that all such forward-looking statements involve risks and uncertainties,
including, without limitation, the risks that the FDA will not approve any of our products, risks related to our products, expected
product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments
and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, the results and timing
of clinical trials, patient acceptance of Lipocine&rsquo;s products, the manufacturing and commercialization of Lipocine&rsquo;s
products, and other risks detailed in Lipocine&rsquo;s filings with the SEC, including, without limitation, its Form 10-K and
other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at&nbsp;www.sec.gov. Lipocine assumes no
obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Morgan Brown</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Vice President &amp; Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (801) 994-7383</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>mb@lipocine.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hans Vitzthum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (617) 430-7875</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>hans@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2039447d3_8kimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2039447d3_8kimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !< 0L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MOF+_ ()Q?\%0_"/_  4E_P"$R_X172/$FE?\(9]B^U?VM:PP>;]J^T;-GESR
MYQ]G;.=N,C&<G'T[0 445\=?L1_\%E/ O[<7[1>H?#CP]H7BS3]4TZRN;UY]
M1LK>*W98)$C8!DN9&R2XQ\@Z'D4 ?8M%?GK^T)_P<0_#']G?XX^*_ NI^&/'
MEUJ/A/5)]+N9K73;1X9'B<J2C->*Q7(X)4'V%<=_Q%#?"+_H4/B/_P""JR_^
M3J /T[HKX,^!W_!Q?^SI\6M9@T[5;[Q3X&N)F$:W&OZ6J6CN<#_66\LX1<G[
MTFT#!R0*^[=.U&WU?3X+NTGANK6ZC6:&:%P\<R,,JRL."""""."#0!-117RU
M^VM_P6"^"?[$DEYI6N>)#KGB^W!4Z#H<2WUY _3$WSI'"1D$K)(K$= : /J6
MBOR&U?\ X.AK/^T)/L'A"Y^RY_=_:-*7S,>^+[%>K?LY?\'*OP=\>7]OIOCR
MV\1^$KNX?;_:)T@'38O][R[B:8<]]F!W(H _2.BL7X>_$;0/BSX/LO$'AC6M
M,\0:'J*>9:W^GW*7%O..AVNI(.#D$=B"#S6U0 44C,$4DD  9)/:OB']LS_@
MO5\$?V7-6DT'2M7N?'?B2)FCGC\/VZ7UI8,.TLQFBC)SD;8W<J00P6@#[?HK
M\@6_X.AHOM1QX0D\G?QG2ANVY_Z_L9Q7T7^S#_P<-_ 3XY:I;:1X@U+6/ 6K
M3L(TFUS3UM["9SV$T4LRQC_:F*+[T ?>=%0Z=J-OJ^GP7=I/#=6MU&LT,T+A
MXYD895E8<$$$$$<$&OF?Q/\ \%1/"/A?_@H;I_[.LND>(W\4:AY6R]2TA-@N
M^T-T,R&<2?<&/]4>?;F@#Z>HKX=_;9_X+H_#S]B#]H?5OAUX@\.^,]0U328;
M>>2?3["VEMV$T*RKAGNHVR XS\@Y]>M?4G[+_P"T/H7[5_P"\,?$+PV9_P"R
M/$UH+F))T5)H&#%)(W568!T=64@,1E>IZT =]1110 45\=?\$^/^"RG@7_@H
M=\9]3\%>&-"\6:9?Z9HLNMR2ZI96\,+11SP0E08[F4[MUPIQM P#SV/F/QM_
MX.-?A=\#_C/XN\%:AX6\?7%_X0UJ\T2YEM]-M'AEEMIWA=D+7BDJ60D$JIQC
M('2@#]$Z*_,3_B*&^$7_ $*'Q'_\%5E_\G4?\10WPB_Z%#XC_P#@JLO_ ).H
M _3NBOC7X0?\%?\ PY^T=^ROKOQ \':'K5O=VGB.T\):?::Q9Q1B:_N3"(V<
M1W+#R5$NYCO#81MJLVT-K?\ !/'_ (*0W?[97B>XTS5='BTF:YTV74]-$, 7
M*6YM%N5D87$J[@;ZU9=IQB1@3O1T4 ^M**** "BBB@#\??\ @U#_ .:]_P#<
MO?\ N4K]@J_'W_@U#_YKW_W+W_N4K]@J "OP<_X-XO\ E*KXI_[%_5__ $KM
MZ_>.OP<_X-XO^4JOBG_L7]7_ /2NWH [?]D/X(>#_P!H#_@X!^.VA>-_#>C^
M*M&6XUZZ6RU.U6XA$JWL(5]K C< S 'W-?IHO_!+W]G5%8?\*4^&WS#!SH4!
M[@\?+QTK\]/^"<?_ "L6_'C_ +F#_P!+K>OV#H ^#/VS/^#?CX*?M ^"K^7P
M)HUO\,_&2HSV5WIK.-/FD .V.>V)*",GJT05AP?F VGP[_@W/_;8\2?\)+XH
M_9T\=75Q+=^$XI;KP_\ :Y,RV2P2B*ZL,GDJC,KHO\($H^Z%"_K#-.EM"TDC
M+''&I9F8X"@=23Z5^"G_  2N\86_B?\ X*Z_%;XPVX>3PIX2MO%?C2\G1?E-
MI(TVP!N@+"8$>H5O0D 'UM_P7H_X*?\ BGX&ZAI/P4^$M\\?C/Q1;>9K-[IC
M&74=.BD;9#:P!,M'/+\QS]]4*%0#(&'G7_!-O_@W3BU:ST[QY^T')=S7-YMO
M8?!\4K(1N&X?;Y@=^XYR8D*D$?,YRR#%_P"#>'X7G]JS]KWXL?M >,]FI>(-
M,N=UD9!O6*]U!IGFF3/W3'$GEKZ+,1V%?LO0!Y1X<_81^"7A'28['3OA%\-;
M:VBZ*/#5FQ)]68QDL?<DFO"?VO/^"$WP$_:DT^ZN-.\.0?#CQ-(F(=3\-0K:
MPAAT,EF,0.#_ !$*KMG[]?9M% 'X+?!3Q#\6_P#@WR_;0ATSQU#JNL?"CQ%(
M8;N73VD.F:O W"W< 8;5NX< M&</@,N=KK(?W2\!^/-&^*'@W3?$/A[4K36-
M$UBW6ZLKVUD$D-S$PR&4C_\ 6#D'D5\[?\%D?V;_ /AIW_@G?\0=(@CWZKH5
MG_PD>F_+N;S[/,S*H_O/$)8Q_P!=*_.3_@CU_P %#-0^ ?\ P3,_:)TN6\*W
MGPXL1K/AIY#G[/-?[K9% /\  MWY+XQR9VYYH L_\%AO^"I7C;]K7XYW?[/G
MP/.KW.AQ7;:/J3Z.C->>*+Q6*RP(5^;[*A!4XP),.S$Q[:]Y_P""<'_!NYX0
M^$OA^#Q)\<K2R\:>*[N-)(]!WL=,T4]2KE6Q<R=CG]V.0 W#G+_X-D_V1[/P
MW\%_$GQHU2W6;7?%EY)HVE32#<T%C P\YE)[RS@ANO\ Q[KZFOU-H \MB_8>
M^"T.E?84^$7PQ6S\LQ>2OA>Q";",$8\KI7R-^V?_ ,&ZOP?^.VC76H?#B-OA
M?XKVL\2VK/-I%T_4"6W8DQCH,PE0O)V/TK]"Z* /QF_X):?MX>,/^"8_[0$O
M[,/QZMCI>A'4/*TG4IYLQ:++,<H1(?E:QF)#!QCRV<DX!?9K?%__ )6E?"__
M &Z?^F-Z_8.OQ\^+_P#RM*^%_P#MT_\ 3&] '@/_  6B\ P?%?\ X+;2^%[F
M>6UMO$EYX=TJ6:( O"D\%M$S*#QD!B1GTKUG_@D3^UMJO_!,G]LGQ=^S-\5]
M2CM/#5QJ\EO87]S)Y5KIU^,>7,I?&VWNX]A!/ 8QGC<YKA/^"IO_ "L#Z!_V
M,'A3^5G7V?\ \%__ /@FJ/VH?@HWQ2\)6'F>/O -HS7<,,>9-9TM=SO& .6D
MARTB=ROF* 25P ?HF#N&12U^='_!O'_P4&N_VF_@%>?#+Q/<-<>*_AG;PI9W
M4C9?4=+8E(L\Y+P$"-CCE6AZL6-?HO0!^#G_  :\_P#)_GB__LG][_Z<=-K]
M>?%7_!.+X"^./%&I:UK'PB\ :EJ^L74M]?7EQH\+S74\KEY)'8C)9F8DD]23
M7Y#?\&O/_)_GB_\ [)_>_P#IQTVOWCH \&_X==?LZ?\ 1%?AO_X(X/\ XFC_
M (==?LZ?]$5^&_\ X(X/_B:]YHH \HMOV'?A-I7P@UKP'IG@30=#\*Z_.EW>
MV6E0_8-]PA1H[A7A*NDR-'&RR*0RE%(((%/_ &??V./!/[-NNZIK&A6U]=:]
MK,$-I=:IJ-R;BY:WB55C@7@*D:A5X11NVKN)V+CU2B@ HHHH **** /Q]_X-
M0_\ FO?_ '+W_N4K]@J_'W_@U#_YKW_W+W_N4K]@J "OP<_X-XO^4JOBG_L7
M]7_]*[>OWCK\'/\ @WB_Y2J^*?\ L7]7_P#2NWH ]@_X)Q_\K%OQX_[F#_TN
MMZ_3C]KJ/XG_ /"A-;F^#L^AIX_LU6XT^#5X/,MKX*<O 3N4([KD*Q. VW)
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M*^1/^#7G_D_SQ?\ ]D_O?_3CIM?O'0!^5G_#AGX_?]'>>+_^^M1_^3*]*_9
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M^"P38 _Z\444 ?!/_!7G_@BYI?[><3^./!<UGH'Q2LK81.TWR6?B&-/N1SD
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MX]M+:Z^+6LQ/'M683Q>'K9^L,;#Y3,X_UD@)'\"G;N+_ #M\7_\ E:5\+_\
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M%%%%0= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2039447d3_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2039447d3_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !1 /H# 2(  A$! Q$!_\0
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M8;G>[ ;8_P!%* "OP<_X->?^3_/%_P#V3^]_]..FU^\=?@Y_P:\_\G^>+_\
MLG][_P"G'3: /WCHHHH _!SX'?\ *S!>_P#90=;_ /1%W7L'Q?\ ^5I7PO\
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MEMS0 _\ X*,_ GQ;_P $K?VQ/ W[27PRM([;PKXD-O/<V]OE;>*]:!?M=I.
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MIAX6\::YHM@W@+PS>:M$-535;9Y)X)+&\MX)?)5_,!=I(\C;E=W(&#7['44
M?D-_P5"_9*_X*$?$W]NCQQKGP/\ %WBK3/A=>_8/[%MK/QM#IT,6S3[9+C;
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M3<;16MEK]USEPN#Q4*BG.;:YYOETM9N5M=^JTOI\C>HHHKD/9"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
